Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present data at PAINWeek 2025 regarding the impact of diabetic peripheral neuropathic pain (DPNP) on patients. The presentation, scheduled for September 4, 2025, will showcase insights from a patient survey related to the development of Pilavapadin.
The study focuses on patients' experiences with DPNP despite using current pain relief options. The presentation highlights that diabetic neuropathy affects nearly 50% of diabetes patients during their lifetime, with 25-30% suffering from DPNP specifically, characterized by burning, tingling, and numbness that significantly impacts quality of life.
Positive
- None.
Negative
- None.
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada.
Presentation details:
- Poster #53: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin
- Date: September 4, 2025
- Time: 4:00 p.m. – 5:30 p.m. PST
- Location: Exhibit Hall (Level 4)
- Presenters: Belinda Hardin, PharmD, BCPS, Senior Director, Medical Communications, and Suma Gopinathan, M.S, Ph.D., Senior Vice President, Discovery, Lexicon Pharmaceuticals
Diabetic neuropathy is a major complication affecting individuals with both type 1 and type 2 diabetes, with nearly half of all patients experiencing it during their lifetime. Among these patients, approximately 25
About Pilavapadin
Discovered using Lexicon’s unique approach to gene science, pilavapadin is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signaling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.
Pilavapadin has received Fast Track designation from the U.S. Food and Drug Administration for development in diabetic peripheral neuropathic pain (DPNP).
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates, including pilavapadin. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What will Lexicon Pharmaceuticals (LXRX) present at PAINWeek 2025?
How common is diabetic peripheral neuropathic pain among diabetes patients?
Who are the presenters for Lexicon's DPNP study at PAINWeek 2025?
What symptoms characterize diabetic peripheral neuropathic pain according to LXRX's presentation?
